Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Multiple Sclerosis
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
November 19th, 2007
Patients with relapsing-remitting multiple sclerosis (MS) treated with 250 mcg Betaseron (interferon beta-1b) experienced less injection site pain and fewer injection site reactions than those treated with 44 mcg Rebif. Moreover, among those who experienced injection site pain, significantly more patients on Rebif versus Betaseron said that pain negatively influences their satisfaction with treatment. These results from the BRIGHT (Betaseron(R) versus Rebif(R) Investigating Higher Tolerability) study were published in this month's issue of Multiple Sclerosis. "BRIGHT is the first large-scale study to compare injection site reactions and pain with two high-dose...
Source: Pain & Central Nervous System Week (2007-11-19)
|
